Cure My Disease

Don't miss your cure!

 Log in / Sign up

Gene therapy particles aim to boost stroke recovery

NCT ID NCT06995625

Recruiting now Disease control Sponsor: S&Ebio Co. Ltd. Source: ClinicalTrials.gov ↗

First seen Jul 06, 2026 · Last updated Jul 07, 2026 · Updated 1 time

Summary

This early-stage trial tests a new drug called SNE-101 in people who have had an acute ischemic stroke within the past five days. The main goal is to see if SNE-101 is safe and tolerable, and to find the highest safe dose. The study also looks at whether SNE-101 can improve motor function and movement after a stroke. Only a small number of participants will be enrolled to gather initial safety data.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
SNE-101 (a type of gene therapy particle)
What this could lead to
If safe and effective, SNE-101 could become a new treatment to help stroke patients recover motor function.
What could go wrong
This is a very early, small Phase 1 trial focused on safety, not proof of benefit. The treatment may not work or could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE ISCHEMIC STROKE AIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

ischemic stroke stroke disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ACUTE ISCHEMIC STROKE AIS

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Ajou University Hospital

    RECRUITING

    Suwon, Gyeonggi-do, 16499, South Korea

    Contact

  • Ewha Womans University Seoul Hospital

    RECRUITING

    Seoul, 07804, South Korea

    Contact

  • Samsung Medical Center

    RECRUITING

    Seoul, 06351, South Korea

    Contact

    Contact

    Contact

    Contact

More trials for these conditions

Other studies related to the condition(s) this trial covers.